Question 1

Is cell therapy safe and effective?

Accepted Answer

Cell therapy is considered safe and clinically effective when performed under proper medical supervision and according to established protocols. The procedure is well tolerated by most patients.
Mild side effects may occasionally occur after administration, such as temporary burning at the injection site, redness, or a slight increase in body temperature. These reactions are generally short-lived and are commonly associated with the body’s immune response to the administered cells, indicating active biological interaction.

Clinical outcomes depend on the individual condition, disease stage, and treatment goals, but many patients report measurable functional improvements following therapy.

Question 2

What are the significant results of the therapy?

Accepted Answer

Depending on the condition, disease stage, and individual response, therapy may lead to:
 • stopping of disease progression
 • reduction of functional deterioration
 • improvement in motor, cognitive, or neurological functions
 • decreased severity of clinical symptoms
 • enhanced physical endurance and stress resistance
 • improved tissue regeneration and recovery capacity
Many patients report a noticeable improvement in quality of life, including better daily functioning, increased energy levels, improved sleep, and overall physical resilience. In chronic and degenerative conditions, the primary therapeutic goal is often to stop or significantly slow further decline and preserve remaining function, which cell therapy is specifically designed to support.
Clinical outcomes vary between individuals and depend on age, baseline health status, lifestyle, and disease severity, but the therapy is widely used to achieve meaningful functional improvement rather than temporary symptomatic relief.

Question 3

Is cell therapy (CT) suitable for everyone? What are the indications and contraindications for this treatment?

Accepted Answer

Cell therapy is not a universal treatment and is prescribed only after a comprehensive pre-treatment medical evaluation to determine eligibility and safety.
It may be considered as part of a personalised medical approach for selected chronic, degenerative, inflammatory, or regenerative indications, including supportive and preventive medical strategies, when clinically justified.
Contraindications include, but are not limited to: pregnancy, acute infections, decompensated cardiovascular conditions, advanced renal failure, active malignancy, ongoing chemotherapy, radiotherapy or intensive immunosuppressive therapy.
The final decision is made individually by qualified physicians based on a risk–benefit assessment, ensuring that cell therapy is applied only when medically appropriate and safe.

Question 4

Are there pre-existing conditions that may reduce the effectiveness of cell therapy?

Accepted Answer

Yes. The effectiveness of cell therapy varies between individuals and depends on multiple patient-specific factors. These include the severity and stage of the disease, overall health status, immune system function, metabolic conditions (such as diabetes), genetic background, lifestyle factors, and adherence to medical recommendations.
For this reason, expected outcomes are always assessed individually, and treatment goals are defined based on a comprehensive medical evaluation rather than a standardised expectation.

Question 5

Is it possible that a patient may be considered unfit for cell therapy despite already being in the clinic?

Accepted Answer

Yes. Even after prior screening, final eligibility is always confirmed immediately before treatment. If there are changes in the patient’s condition—such as signs of acute infection, fever, or other clinically relevant changes—treatment may be postponed or cancelled for safety reasons.
A final medical assessment, including consultation and, if necessary, additional laboratory tests, is performed on-site to confirm that cell therapy remains medically appropriate and safe at the time of administration.

Question 6

How will patients be followed after cell therapy? Are the results difficult to monitor?

Accepted Answer

Post-treatment follow-up is an integral part of our medical protocol and is conducted in a structured and continuous manner. Each patient is assigned a dedicated medical specialist who oversees recovery, functional dynamics, and overall well-being after cell therapy.
Following treatment, patients enter a personalised medical rehabilitation and follow-up phase, designed to support and consolidate therapeutic effects. Monitoring includes both:
 • qualitative assessment — functional improvements reported by the patient (mobility, endurance, cognition, daily activities)
 • quantitative assessment — objective clinical and laboratory indicators compared before and after therapy
To enhance precision, patients may use a medical-grade wearable monitoring device, allowing continuous tracking of key physiological parameters and recovery dynamics. This data supports clinical decision-making and enables timely adjustments to medical recommendations.
This comprehensive follow-up ensures that results are clearly monitored, medically interpreted, and translated into meaningful functional outcomes, rather than left to subjective observation alone.

Question 7

Why is real stem cell therapy expensive?

Accepted Answer

Real stem cell therapy is not a single procedure, but a comprehensive, patient-specific medical process that integrates advanced diagnostics, laboratory biotechnology, structured clinical protocols, and long-term medical responsibility.
The cost reflects the depth of medical personalisation, scientific complexity, safety standards, and rehabilitation support required to work ethically and effectively with living cellular material.

1. Fully personalised medical treatment protocols
Each patient receives an individualised therapeutic strategy, not a standardised procedure.
Before any laboratory work begins, physicians carefully review medical records, imaging, laboratory data, and disease history. The treatment protocol is designed according to diagnosis, disease stage, functional status, and individual biological response capacity.
This level of personalisation requires significant medical expertise, time, and multidisciplinary involvement.
2. Structured proprietary treatment protocol
Cell administration is performed strictly according to a multi-stage proprietary clinical protocol, developed internally based on scientific evidence and accumulated clinical experience in regenerative medicine.
The protocol defines:
 • timing and sequence of cell administration
 • integration with supportive biological or neuromodulatory therapies when indicated
 • safety checkpoints and clinical decision points
This structured approach ensures clinical consistency, reproducibility, and controlled outcomes, rather than isolated or experimental interventions.
3. Advanced biomedical technology and specialised medical expertise
Stem cell therapy involves the clinical use of living biological material and therefore requires the continuous involvement of highly qualified physicians, laboratory scientists, and cell-culture specialists trained specifically in regenerative medicine.
Such expertise is rare and must be supported by advanced medical infrastructure and ongoing professional training.
4. Strict multi-level safety and quality control
Every biological sample (bone marrow, peripheral blood, placental tissue, etc.) is processed only after comprehensive medical screening of the patient.
Each stem cell preparation undergoes:
 • sterility testing
 • viability assessment
 • identity and traceability control
A documented quality certificate is issued for each individual cell dose, ensuring compliance with medical safety and laboratory standards.
5. Complex laboratory processing and controlled cell expansion
Stem cells are not administered immediately after collection. The laboratory process includes:
 • isolation of the target cell population
 • cultivation under sterile conditions using medical-grade culture media
 • controlled expansion to achieve a clinically effective dose
This process typically requires 2–3 weeks, depending on the patient’s biological characteristics, cellular proliferation capacity, body weight, and clinical indication.
All culture media, reagents, and consumables are single-use and high-cost, as required by medical laboratory regulations.
6. Use of laboratory-guided neuro-induced stem cells
In selected neurological cases, stem cells undergo laboratory-guided neuro-induction, enhancing their supportive interaction with the central nervous system.
This method requires additional laboratory steps, specialised expertise, and strict validation procedures and is currently applied only in a limited number of specialised medical centres worldwide.
7. Cryopreservation for potential future treatment cycles
Excess cultivated cells may be cryopreserved under controlled laboratory conditions, allowing additional treatment cycles if clinically indicated.
Cryopreservation enables:
 • consolidation of achieved results
 • continuation of therapy without repeated biological collection
This process requires specialised equipment, continuous monitoring, and strict documentation.
8. Integrated medical rehabilitation and post-treatment optimisation
Stem cell therapy is not treated as a standalone intervention. Following cell administration, patients enter a structured medical rehabilitation and optimisation phase.
Depending on the condition, this may include:
 • individually adapted neuro-rehabilitation or physical therapy
 • functional monitoring and clinical reassessment
 • targeted medical recommendations to support neuroplasticity and tissue recovery
Rehabilitation is medically supervised and adjusted according to the patient’s clinical dynamics, ensuring that biological effects translate into meaningful functional improvement.
9. Long-term clinical coordination and follow-up
Each patient is supported by a dedicated medical coordinator from the first consultation and for up to six months after cell administration.
This ensures:
 • continuity of care
 • monitoring of clinical progress
 • timely medical guidance during recovery
Long-term supervision is an essential component of responsible regenerative medicine.
10. Diagnostic confirmation using modern medical equipment
Before treatment begins, the diagnosis and current clinical status are re-evaluated using modern diagnostic technologies.
This confirms that the selected protocol is medically justified, appropriate, and safe.
11. Comprehensive clinical logistics and international medical deployment
For patients who are unable to travel or for whom transportation poses medical risks, treatment may be delivered through direct medical deployment.
A specialised medical team trained in regenerative medicine can travel to the patient’s location, performing clinically appropriate stages of therapy under controlled conditions. This requires:
 • international coordination of medical staff
 • regulated transport of certified biological materials
 • portable medical equipment and sterile, single-use consumables
 • adherence to international standards for cellular therapy outside a clinic setting

Clear Medical Answers About Cell Therapy

Journey to Recovery
Starts Here

+48 223 07 48 82 (EN/RU/PL)

+39 327 20 83 229

+33 423 11 00 21

Clear Medical Answers About Cell Therapy

Journey to Recovery Starts Here

Journey to Recovery
Starts Here